<DOC>
	<DOCNO>NCT01989234</DOCNO>
	<brief_summary>This multi-center , randomize , double-blind , placebo-controlled study YKP10811 capsule patient chronic idiopathic constipation . Following 2-week baseline period , approximately 320 eligible patient &lt; 3 complete spontaneous bowel movement ( CSBM ) ≤ 5 SBMs per week randomly assign equally receive one follow oral treatment ; placebo YKP10811 capsule daily 12 week follow 2 week follow-up period . The objective study : - To assess efficacy YKP10811 daily relieve constipation associate symptom subject chronic idiopathic constipation . - To determine safety tolerability YKP10811 daily subject chronic idiopathic constipation .</brief_summary>
	<brief_title>A Multicenter , Double-Blind , Randomized , Placebo-Controlled , 12-Week , Dose-Range-Finding Trial YKP10811 Capsules Administered Once Daily Subjects With Chronic Idiopathic Constipation</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<criteria>Patients meet modified Rome II criterion Chronic Constipation . Patients male female , 18 65 year age inclusive . At Visit 3 , patient must &lt; 3 CSBMs per week ≤ 5 SBMs per week 2week baseline period . Patients meet Rome II criterion Irritable Bowel Syndrome ( IBSC ) . Patients constipation druginduced , secondary endocrine , metabolic , surgery . Patients clinically significant disease would limit patient 's ability complete and/or participate study , include gastrointestinal disorder surgery , endocrine abnormality ( e.g. , diabetes ) , impaired renal function ( GFR &lt; 55mL/minute/1.73m2 ) , uncontrolled pulmonary disease ( include asthma ) , uncontrolled cardiovascular disease ( history myocardial infarction cerebrovascular accident within 6 month prior screen ) significant neurological disease . Patients history inflammatory bowel disease . Patients history cancer ( basal cell squamous cell carcinoma skin completely excise ) unless malignancy complete remission least 5 year prior screen . Patients start special diet and/or intense physical workout program within 30 day prior begin baseline period intend substantially modify dietary habit time study ( patient stable , continuous regimen fiber therapy least 30 day prior pretreatment baseline period allow continue therapy , provide continue constant dose throughout study . Patients history clinically significant hypersensitivity allergy ( facial swelling , hive , breathe difficulty , StevensJohnson syndrome etc ) , response medication , either prescription nonprescription include investigational drug , dietary supplement , herbal medicine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>